Upsher-Smith selects PANTHERx Rare to distribute Torpenz

PANTHERx Rare, a dual-accredited specialty pharmacy, was selected by Upsher-Smith for the distribution of Torpenz (everolimus) Tablets for the treatment of Tuberous Sclerosis Complex.

Torpenz Tablets are an oral kinase inhibitor FDA approved for the treatment of adult and pediatric patients aged one year and older with TSC who have subependymal giant cell astrocytoma requiring therapeutic intervention but cannot be curatively resected. In addition, it is approved for the treatment of adults with renal angiomyolipoma and TSC not requiring immediate surgery.

[Read more: Upsher-Smith previews expansion of rare disease portfolio at 2024 AAN annual meeting]

"When people have a chronic rare disease, they think about it every day and so do we. We recognize the complex and sometimes frightening nature of such diseases to which our patients and their families are learning to adapt. We look forward to working hard with Upsher-Smith to ease the burden and decrease stress so patients can focus on feeling as healthy as possible," said Bansi Nagji, CEO of PANTHERx Rare Pharma.

[Read more: Upsher-Smith, NASPA recognize 47 pharmacists with 2022 NASPA Excellence in Innovation Award]